ALDX stock news

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced enrollment of the first patient into the Phase 3 INVIGORATE Trial of topical ocular reproxalap in patients with allergic conjunctivitis. “Initiating enrollment in the INVIGORATE Trial moves us closer to our goal of providing allergic conju Read more
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced the appointment of Nancy Miller-Rich to the company’s board of directors. “Nancy brings enterprise-wide strategic thinking and business development expertise over more than 35 years in the pharmaceutical industry, including senior roles wi Read more
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced enrollment of the first patient into the Phase 3 GUARD Trial of ADX-2191 for the prevention of proliferative vitreoretinopathy (PVR). PVR is a serious, sight-threatening retinal disease with no approved treatment. “Initiation of patient en Read more
Aldeyra Therapeutics Inc. shares rose more than 13% in premarket trade Tuesday before surrendering their gains, after the biotech reported positive results… Read more
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, announced today positive top-line results from Part 1 of the adaptive Phase 3 RENEW Trial of topical ocular reproxalap in patients with dry eye disease. “To our knowledge, reproxalap is the first topical dry eye disease drug to demonstrate statistically s Read more
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Tuesday, December 3, 2019, to provide top-line results from Part 1 of the adaptive Phase 3 RENEW Trial of topical ocular reproxalap in patients with dry eye disease. The dial-in numbers are (866) 211-4098 for domestic callers and (647) 689-6613 for international callers. The Conference ID is 1592481. A live audio webcast of the conference call will also Read more
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the following healthcare investor conferences in November: Stifel 2019 Healthcare Conference Lotte New York Palace Hotel New York, N.Y. Tuesday, November 19, 20 Read more
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today reported financial results for the quarter ended September 30, 2019. In addition, the company updated investors on anticipated clinical milestones. “Aldeyra continued to make significant progress during the quarter in advancing our immunology platfo Read more
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that the company will host a conference call on Thursday, November 7, 2019, at 8:00 a.m. ET to discuss financial results for the quarter ended September 30, 2019 and provide a corporate update. The dial-in numbers are (866) 211-4098 for do Read more
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to im Read more
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Thursday, October 31, 2019 to release expa Read more

4 Stocks To Watch For October 14, 2019

03:51am, Monday, 14'th Oct 2019
Some of the stocks that may grab investor focus today are: Aldeyra Therapeutics Inc (NASDAQ: ALDX) will present Phase 3 data for reproxalap in allergic … Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 27) Castle Biosciences Inc (NASDAQ: CSTL ) The Medicines Company (NASDAQ: MDCO ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 27) Abeona Therapeutics Inc (NASDAQ: ABEO ) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alimera Sciences Inc (NASDAQ: ALIM ) AnaptysBio Inc (NASDAQ: ANAB ) ASLAN PHARMACEU/ADR (NASDAQ: ASLN ) Assembly Biosciences Inc (NASDAQ: ASMB ) Cancer Genetics Inc (NASDAQ: CGIX ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Clearside Biomedical Inc (NASDAQ: CLSD ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI )(announced that its current cash position will be sufficient to complete enrollment in all three patient groups of its two ongoing Phase 2 trials for its lead compound VAL-083, which is likely to occur by the fourth quarter of 2020) ICU Medical, Incorporated (NASDAQ: ICUI ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Mallinckrodt PLC (NYSE: MNK )(reacted to an unfavorable ruling on a patent infringement lawsuit regarding its inhaled nitric oxide product) Neuralstem, Inc. (NASDAQ: CUR ) Novus Therapeutics Inc (NASDAQ: NVUS ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Regenxbio Inc (NASDAQ: RGNX ) Revance Therapeutics Inc (NASDAQ: RVNC )(announced an amended agreement with Mylan NV (NASDAQ: MYL ), … Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 15) Novocure Ltd (NASDAQ: NVCR ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 15) AbbVie Inc (NYSE: ABBV ) Acer Therapeutics Inc (NASDAQ: ACER ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Alector Inc (NASDAQ: ALEC ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) BioTelemetry Inc (NASDAQ: BEAT ) Cellectis SA (NASDAQ: CLLS ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI )(announced pricing of its $6.5 million common stock offering at $1 per share) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Genetic Technologies Limited (NASDAQ: GENE ) GENFIT S A/ADR (NASDAQ: GNFT ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Ironwood Pharmaceuticals, Inc. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 25) ArQule, Inc. (NASDAQ: ARQL ) Zai Lab Ltd (NASDAQ: ZLAB ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 25) AbbVie Inc (NYSE: ABBV )(announced a deal to buy Allergan plc (NYSE: AGN ) for $63 billion) Acer Therapeutics Inc (NASDAQ: ACER )(The FDA issued complete response letter to its rare disease drug Edsivo) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aldeyra Therapeutics Inc (NASDAQ: ALDX )( reported negative results for the late-stage study that evaluated its reproxalap in anterior uveitis) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Axcella Health Inc (NASDAQ: AXLA ) Biopharmx Corp NYSE: (BPMX) (reported positive results for a Phase 2b clinical trial of BPX-04 in treating moderate-to-severe papulopustular rosacea) CELYAD SA/ADR (NASDAQ: CYAD ) Conatus Pharmaceuticals Inc (NASDAQ: CNAT )( announced decision to explore strategic alternatives following failed NASH drug trial) Enochian Biosciences Inc (NASDAQ: ENOB ) Evolent Health Inc (NYSE: EVH ) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Myriad Genetics, Inc. Read more

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

Proudly Made At

ROCKIT